Incyte Corporation INCY
Composite 78/100; the shares have moved about 33% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Its least supportive area is Income at 50 — still above average.
Growth ranks 96/100 — a strong point in its favour. Balance-sheet strength ranks 95/100 — a strong point in its favour. Momentum ranks 74/100 — a moderate point in its favour.
Its least supportive area is Income at 50 — still above average.
What the company does Incyte discovers, develops, and commercializes small-molecule therapeutics for oncology and hematologic diseases. Its marketed drugs include JAKAFI for myelofibrosis and polycythemia vera, PEMAZYRE for biliary tract cancer, and ZYNYZ for Merkel cell carcinoma. The pipeline spans next-generation JAK inhibitors and targeted agents in MPNs, solid tumors, and graft-versus-host disease.
Key financials Incyte posts gross margin 55.7%, operating margin 41.9%, and net margin 27.7%. Revenue grew 21.2% while EPS surged 4038.2%. ROE is 30.7% and ROA 16.8%, with a strong Piotroski F-Score of 7/9. Debt/Equity is 0.01 and the current ratio is 4.59.
Stock health Momentum is positive over 3m 28.56%, 6m 22.81%, and 12m 46.59%, with RSI(14) at 53.50. The stock is 6.21% below its 52-week high. SideraVIA scores Quality 79.4, Growth 95.5, Strength 94.4, and Momentum 77.4.
Price vs fair value The stock trades at a discount of 2.20% versus the analyst mean target of 127.12. - Incyte faces competitive scrutiny in KRAS programs versus Revolution Medicines (Insider Monkey 2026-08-28). - Recent Zacks coverage highlights modest post-earnings moves (+0.8%) and peer outperformance in gene therapy (Zacks 2026-08-27/28).
Looking forward Forward P/E of 41.67 reflects high near-term expectations. Pipeline catalysts in MPNs and solid tumors could re-rate valuation if readouts meet or exceed expectations. Execution risk remains tied to clinical timelines and payer dynamics for oncology assets.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.